Complications of successively double autologous hemopoietic stem cell transplants.
- Author:
Wen-Rong HUANG
1
;
Wan-Ming DA
;
Bo-Long ZHANG
;
Chun-Ji GAO
;
Xiao-Ping HAN
;
Yu JING
;
Xiao-Xiong WU
;
Yu ZHAO
;
Hong-Hua LI
;
Quan-Shun WANG
;
Yi-Zhuo ZHANG
;
Jian BO
Author Information
1. Department of Hematology, General Hospital of PLA, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Hematologic Neoplasms;
surgery;
Hematopoietic Stem Cell Transplantation;
adverse effects;
methods;
Humans;
Male;
Oral Ulcer;
etiology;
Peripheral Blood Stem Cell Transplantation;
adverse effects;
methods;
Platelet Transfusion;
statistics & numerical data;
Reproducibility of Results;
Retrospective Studies;
Transplantation, Autologous
- From:
Journal of Experimental Hematology
2005;13(1):30-34
- CountryChina
- Language:Chinese
-
Abstract:
In order to get clinical information about safety and feasibility of successively double autologous hemopoietic stem cell transplants (SD-AHSCT) in malignant hematological disease patients, the complications and hematological reconstitution after SD-AHSCT in 20 patients were analyzed retrospectively. 20 patients with hematologic malignancies received autologous peripheral blood stem/progenitor cell transplantation at the first transplant, and then were given autologous bone marrow transplantation as the second transplant at 4-10 months. The results showed that all the patients tolerated mobilization and collection of peripheral blood stem/progenitor cells as well as bone marrow collection. All the patients got enough hematological stem/progenitor cells for SD-AHSCT and achieved hematological reconstitution after SD-AHSCT. The speed of hematological reconstitution was positively correlated with the transfused quantity of hematological stem/progenitor cells (r = 0.968). The hematological reconstitution after the first autologous hemopoietic stem cell transplant (AHSCT) was earlier than that of the second (P < 0.05). There was no statistical difference between the first and the second AHSCT for the incidence of skin or mucous membrane bleeding (P > 0.05). No patients occurred massive hemorrhage during SD-AHSCT. The quantity of platelet transfusion in the second AHSCT was larger than that in the first AHSCT (P < 0.01). The incidence of oral ulcer in the first AHSCT was significantly higher than that in the second (P < 0.01). No statistical difference between the first and the second AHSCT was there in infectious sites, infectious pathogens and infection incidence (P > 0.10). All the complications were improved or cured, and no patients died of SD-AHSCT complications. In conclusion, SD-AHSCT is safe and feasible, and worthy to be further popularized.
